Randomized Trial Backs HIF-2a Inhibition in Advanced RCC
MADRID — Treatment with the hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan (Welireg) in advanced, heavily pretreated kidney cancer led to superior outcomes when compared with an older kinase inhibitor, a phase III trial demonstrated. Final progression-free survival (PFS) analysis showed a 26% reduction in disease progression or death with belzutifan versus everolimus (Afinitor), despite an […]
FDA Approves First Drug for Von Hippel-Lindau-Associated Tumors
The FDA has approved the first therapy for cancers associated with von Hippel-Lindau (VHL) disease. Belzutifan (Welireg), distributed by Merck, targets hypoxia-inducible factor 2α, which drives growth of malignant and benign tumors in VHL. In the absence of approved systemic therapies, most patients with VHL undergo multiple surgeries in their lifetime to remove renal cell […]